First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
在多中心真实世界队列研究中，一线使用帕博利珠单抗治疗PD-L1表达≥50%的非小细胞肺癌患者：PEMBREIZH研究
期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.2806
Amrane, Karim; Geier, Margaux; Corre, Romain; Léna, Hervé; Léveiller, Guillaume; Gadby, Florence; Lamy, Régine; Bizec, Jean-Louis; Goarant, Eric; Robinet, Gilles; Gouva, Sylvie; Quere, Gilles; Abgral, Ronan; Schick, Ulrike; Bernier, Cyril; Chouaid, Christos; Descourt, Renaud
